Disitertide (TFA)

Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer[1][2][3][4][5].

O=C(O)C(F)(F)F.C[C@@H](O)[C@H](N)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(N[C@@H](C)C(N[C@@H](CCSC)C(N[C@@H](CCSC)C(N[C@@H](CCC(N)=O)C(N[C@H](C(O)=O)CC(N)=O)=O)=O)=O)=O)=O)CC1=CNC2=CC=CC=C12)=O)=O)=O)=O)=O)=O)=O)=O

[1]Cindy Neuzillet, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.|[2]Jun Yang, et al. Upregulation of microRNA‑590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor‑β1/phosphoinositide 3‑kinase/Akt signaling. Int J Mol Med. 2019 May;43(5):2212-2220.|[3]Wanming He, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019 Jun;38(23):4637-4654.|[4]Shan Shan Qiu, et al. Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice. PLoS One. 2015 Dec 31;10(12):e0144489.|[5]Gabriel Gallo-Oller, et al. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Cancer Lett. 2016 Oct 10;381(1):67-75.Funct Integr Genomics. 2024 Jul 12;24(4):123.|Int Immunopharmacol. 2024 Aug 21:141:112778.|Acta Histochem. 2023 Feb;125(2):152010.|Cancer Manag Res. 2018 Oct 10;10:4459-4470.|Cell Death Differ. 2021 Jan;28(1):219-232.|Cells. 2019 Jun 25;8(6):635.|Dig Dis Sci. 2020 Jul 15. |Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):9-16. |Front Immunol. 2017 Feb 3;8:91. |Int J Mol Med. 2019 May;43(5):2212-2220. |J BUON. 2021; 26(2): 435-443.|J Exp Clin Cancer Res. 2021 Feb 9;40(1):62.|Oncogene. 2019 Jun;38(23):4637-4654.